在城市HIV门诊中,对可检测到或检测不到HIV病毒血症者开展长效注射抗逆转录病毒治疗的首个示范项目
在旧金山Ward 86 HIV门诊开展首个长效注射抗逆转录病毒治疗(LAI-ART)示范项目,纳入因口服依从性困难而无法维持病毒抑制者。2021年6月至2022年4月共51例启动,39例至少接受2次随访注射;基线病毒抑制者24例100%维持抑制,基线可检测病毒血症者15例中12例(80%)实现抑制,另3例病毒载量下降2 log。
要点
- LAI-ART示范项目纳入因口服依从性困难而无法维持病毒抑制的HIV感染者。
- 基线病毒抑制的24例中100%(95%CI 86%-100%)维持病毒抑制。
- 基线可检测病毒血症的15例中12例(80%,95%CI 55%-93%)实现病毒抑制。
核心结论
- 这项小型LAI-ART示范项目在物质使用率高、住房不稳定的多样化患者中显示出有希望的早期治疗结局,包括因依从性困难而可检测到病毒血症者。
- 需要更多关于LAI-ART在难以触及人群中应用的数据。
研究设计与样本
- Ward 86是旧金山一家大型HIV门诊,服务公共保险和保险不足的患者。
- 患者通过提供者转介、多学科审查(医生、护士、药师)和按时注射监测的结构化流程启动LAI-ART。
- 纳入标准为愿意接受每月注射且有可靠联系方式。
- 2021年6月至2022年4月共51例患者启动LAI-ART,截至数据库关闭时39例至少接受2次随访注射。
主要发现
- 39例随访患者中位年龄46岁,90%为顺性别男性,61%为非白人,41%住房边缘化,54%目前使用兴奋剂。
- 24例基线病毒抑制者(中位CD4计数706 cells/mm3)中100%(95%CI 86%-100%)维持病毒抑制。
- 15例基线可检测病毒血症者(中位CD4计数99 cells/mm3;平均log10病毒载量4.67,标准差1.16)中12例(80%,95%CI 55%-93%)实现病毒抑制。
- 另3例病毒载量在中位22天内下降2 log。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这是一项小型示范项目。
- 需要更多关于LAI-ART在难以触及人群中应用的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting injectable antiretroviral therapy (LAI-ART) is approved for treatment-naive or experienced people with human immunodeficiency virus (HIV; PWH) based on trials that only included participants with viral suppression. We performed the first LAI-ART demonstration project to include PWH unable to achieve or maintain viral suppression due to challenges adhering to oral ART. METHODS: Ward 86 is a large HIV clinic in San Francisco that serves publicly insured and underinsured patients. We started patients on LAI-ART via a structured process of provider referral, multidisciplinary review (MD, RN, pharmacist), and monitoring for on-time injections. Inclusion criteria were willingness to receive monthly injections and a reliable contact method. RESULTS: Between June 2021 and April 2022, 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure (median age, 46 years; 90% cisgender men, 61% non-White, 41% marginally housed, 54% currently using stimulants). Of 24 patients who initiated injections with viral suppression (median CD4 cell count, 706 cells/mm3), 100% (95% confidence interval [CI], 86%-100%) maintained viral suppression. Of 15 patients who initiated injections with detectable viremia (median CD4 cell count, 99 cells/mm3; mean log10 viral load, 4.67; standard deviation, 1.16), 12 (80%; 95% CI, 55%-93%) achieved viral suppression, and the other 3 had a 2-log viral load decline by a median of 22 days. CONCLUSIONS: This small demonstration project of LAI-ART in a diverse group of patients with high levels of substance use and marginal housing demonstrated promising early treatment outcomes, including in those with detectable viremia due to adherence challenges. More data on LAI-ART in hard-to-reach populations are needed.
引用
- Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis. 2023. PMID: 35913500. doi:10.1093/cid/ciac631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。